Prof. Dr. med. Wolfgang Jelkmann (a.D.)

Universität zu Lübeck
Institut für Physiologie
Ratzeburger Allee 160
D-23562 Lübeck

Gebäude 61, Raum 18 (EG)

Phone:+49 (0) 451 3101 7301
Fax:+49 (0) 451 3101 7304

Curriculum vitae


Final Med. School Exam.; Med. School  Hannover, Germany; M.D., 1974


Fellow: Dept. Clin. Biochem., Med. School  Hannover, Germany


Dept. Physiology, Univ. Regensburg, Germany


Dept. Pharmacology, Tulane Univ., New Orleans, USA


Privatdozent: Dept. Physiology, Univ. Regensburg, Germany


apl. Professor: Dept. Physiology, Univ. Lübeck, Germany


Full Professor: Dept. Physiology, Univ. Bonn, Germany


Chairman: Dept. Physiology, Univ. Lübeck, Germany



Research Interests



Production and action of inflammatory cytokines and hemopoietic growth factors with emphasis on erythropoietin, oxygen supply to tissues, high altitude physiology, renal physiology.

Memberships Am. Soc. Hematol., Am. Physiol. Soc., German Physiol. Soc.,  German Soc. Hematol. Oncol.

Member of the editorial board of the journals

1983-1985 Experimental Hematology
1983-1987 Respiration Physiology
1995-1998 Experimental Hematology
1998-2012 Journal of Interferon and Cytokine Research
2003-2017 Annals of Hematology
2003-2005 Drug Design Reviews-Online
2008- Current Medicinal Chemistry
2009-2014 American Journal of Hematology
2010- Open Journal of Hematology
2014- Plos One
Edited books Erythropoietin (W. Jelkmann, A.J. Gross, eds.) Springer, Berlin-New York, 1989



Pathophysiology and Pharmacology of Erythropoietin (H. Pagel, C. Weiss, W. Jelkmann, eds.) Springer, Berlin-New York, 1992


Physiologie (W. Jelkmann, F. Sinowatz, Hrsg.) Deutscher Ärzteverlag, Köln, 1996
Erythropoietin: Molecular Biology and Clinical Use (W. Jelkmann, ed.) F.P. Graham Publishing, Johnson City, TN, 2003
  Rekombinante Arzneimittel (I. Krämer, W. Jelkmann, eds.) Springer, Heidelberg, 2008, 2011 (2. Auflage)
Committees Non-oncologic hematology (DGHO, German Soc. Hematol. Oncol.); Nationale Anti-Doping Agentur (NADA, Bonn)

Representative review articles

Schmid H, Jelkmann W: Investigational therapies for renal disease-induced anemia. Expert Opin Investig Drugs 25(8): 901-16, 2016

Depping R, Jelkmann W, Kosyna FK: Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing. J Mol Med 93(6): 599-608, 2015

Jelkmann W: The ESA scenario gets complex: from biosimilar epoetins to activin traps. Nephrol Dial Transplant 30(4): 553-9, 2015

Elliott S, Sinclair A, Collins H, Rice L, Jelkmann W: Progress in detecting cell-surface protein receptors: the erythropietin receptor example. Ann Hematol 293(2): 181-92, 2014

Jelkmann W: Physiology and pharmacology of erythropoietin. Transfus Med Hemother 40: 302-309, 2013

Jelkmann I, Jelkmann W: Impact of erythropoietin on intensive care unit patients. Transfus Med Hemother 40: 310-318, 2013

Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B: Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Brit J Cancer 106: 1249-58, 2012

Jelkmann W: Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis stimulating treatments. Expert Opin Biol Ther 12(5): 581-92, 2012

Jelkmann W, Lundby C: Blood doping and its detection. Blood 118: 2395-2404, 2011

Jelkmann W: Regulation of erythropoietin production. J Physiol 589: 1251-1258, 2011

Jelkmann W: Biosimilar epoetins and other "follow-on" biologics: Update on the European experiences. Am J Hematol 85: 771-780, 2010

Jelkmann W: Erythropoiesis stimulating agents and techniques: A challenge for doping analysts. Curr Med Chem 16: 1236-47, 2009

Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ: The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67: 39-61, 2008

Bruegge K, Jelkmann W, Metzen E: Hydroxylation of hypoxia-inducible transcription factors and chemical compounds targeting the HIF-a hydroxylases. Curr Med Chem 14: 1853-1862, 2007

Jelkmann W: Erythropoietin after a century of research: younger than ever.
Eur J Haematol. 78:
183-205, 2007

Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR, Jelkmann W: Preclinical studies of erythropoietin receptor expression in tumour cells: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia. Eur J Cancer 43: 510-519, 2007

Hellwig-Bürgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W: Review: Hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interfer Cytokine Res 25: 297-310, 2005

Jelkmann W: Effects of erythropoietin on brain function. Curr Pharm Biotechnol 6: 65-79, 2005

Jelkmann W: Molecular biology of erythropoietin. Intern Med 43: 649-659, 2004

Jelkmann W: The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 69: 265-274, 2002

Klinger MHF, Jelkmann W: Role of blood platelets in infection and inflammation.
J Interfer Cytokine Res
22: 913-922, 2002

Wolber E-M, Jelkmann W: Thrombopoietin: The novel hepatic hormone.
News Physiol Sci
17: 6-10, 2002.

Jelkmann W: Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem 47: 617-623, 2001